G.ST Antivirals is dedicated to the development of therapies against different viruses applying an entirely novel approach of antiviral therapy. The MedUni Vienna spin-off utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply. This leads to an intracellular starvation of the virus, ultimately resulting in highly impaired replication.
Currently, the companies’ focus lies on the application of its strategy for the development of a compound against rhinovirus infections, i.e. the common cold.